Latest News

Class I recall of Abbott Amplatzer delivery sheath


 

Abbott is recalling the Amplatzer steerable delivery sheath, used to deliver the Amplatzer Amulet left atrial appendage occluder during cardiac catheterization, because of an increased risk of air embolism, the Food and Drug Administration has announced.

Air embolism can lead to injuries such as acute reduction in blood flow to the heart (indicated by ST elevation), tachycardia, bradycardia, hypotension, and oxygen desaturation, as well as stroke and death, the FDA said in a recall notice.

Because of the potential for serious injury or death, the agency has identified this as a class I recall, the most serious type.

To date, Abbott has reported 26 incidents, 16 injuries, and no deaths related to this issue.

According to the recall notice, the overall reported incidence rate of observed or potential cases of air embolism during procedures in which the product was used is 0.77%.

The recall includes 672 devices (model: ASDS-14F-075) that were distributed from Oct. 4, 2022, to Feb. 22, 2023.

Abbott sent a medical device recall notice to customers in June asking them to return any remaining unused Amplatzer steerable delivery sheaths to Abbott and to complete an enclosed acknowledgment form.

The company advises use of the fixed curve TorqVue 45° x 45° delivery system for future Amplatzer Amulet left atrial appendage occluder implants.

Customers with questions about this recall should contact their local Abbott representative or Abbott support at 1-800-544-1664 (option 2).

A version of this article appeared on Medscape.com.

Recommended Reading

Hospital patient catches on fire, highlighting need for prevention
MDedge Cardiology
Interventional cardiologists worldwide burned out: Survey
MDedge Cardiology
TAVI turmoil: Did an ANP perform transcatheter aortic valve replacement in the U.K.?
MDedge Cardiology
New AHA statement on ischemia after cardiac surgery
MDedge Cardiology
FDA: No excess mortality risk from paclitaxel stents, balloons for peripheral intervention
MDedge Cardiology
Mixed bag: New performance data on femoral-popliteal artery revascularization
MDedge Cardiology
Expanded coverage of carotid stenting in CMS draft proposal
MDedge Cardiology
Aspirin not the best antiplatelet for CAD secondary prevention in meta-analysis
MDedge Cardiology
Invasive test may cut health care costs related to angina without obstructive CAD
MDedge Cardiology
Same-session PCI rates ‘surprisingly high’
MDedge Cardiology